Christopher Hatch

Abstract Over the past three decades, Hereditary Cancer Testing (HCT) has evolved from single gene assays into multigene panel testing (MGPT), which allows for the screening of all known hereditary cancer genes in a single assay. MGPT is currently the standard approach for clinical HCT. However, with decreasing sequencing costs and increased instrument throughput, the scalability of exome sequencing (ES) and genome sequencing (GS) for HCT indications is becoming more viable.

Keywords organoid islet human pluripotent stem cells vasculature endothelial cells β cells microfluidic device Ca2+ imaging engraftment diabetes Get full text access Log in, subscribe or purchase for full access. References 1. Ingber, D.E. Human organs-on-chips for disease modelling, drug development and personalized medicine Nat. Rev. Genet. 2022; 23:467-491 2. Shamir, E.R. ∙ Ewald, A.J. Three-dimensional organotypic culture: experimental models of mammalian biology and disease Nat. Rev. Mol. Cell Biol.

Abstract Our group has developed and validated an advanced microfluidic platform to improve preclinical modeling of healthy and disease states, enabling extended culture and detailed analysis of tissue- engineered miniaturized organ constructs, or "organs-on-chips." Within this system, diverse cell types self-organize into perfused microvascular networks under dynamic flow within tissue chambers, effectively mimicking the structure and function of native tissues.